Chief Scientific Officer responsible for pharmaceutical discovery and development. Specific achievements subject to Confidentiality Agreement.

Configured company with innovative structure to discover/develop therapeutic assets using licensed technology from U. of Maryland School of Medicine (Prof. Sergei Atamas, MD, PhD) targeting immune system “regulatory hubs” controlling multiple pathways and cell types implicated in fibrogenesis. Selected AVZ-1001 as first pre-clinical asset.CORPORATE STRUCTURE / ASSETS IN SUBSIDIARIES: Designed Delaware company (LLC) structure easily allowing developed assets (ready to be licensed or sold) to be placed into legal subsidiaries.FUNDRAISING: Secured conditional funding from seed investors and VC and secured grant funding through SBIR (phase 1). Negotiated unique payment structures with providers, including $100K in legal services for payment of $120K if/when Series-A funding is obtained - owe $0 if company is unsuccessful in achieving funding.

Took charge to rapidly advance CMC development of lenabasum, delayed in deference to starting phase-III studies. Led efforts to set and operationalize organizational vision and strategy transforming 165-employee company. Redesigned internal operations and organization structure. Directed 65 reports to deliver pre-commercial company-wide operations and change. Reported to CEO.EXECUTIVE LEADERSHIP: Led Executive Leadership Team and collaborated with other executives and Board to develop business strategy and optimize company operations. Defined 3-year Mission & Vision for company, annual Goals & Objectives, and Performance Metrics. Assessed talent and performance and redesigned organizational structure.BUDGETING / PLANNING & ANALYTICS FUNCTION: Created corporate-level Operations Planning & Analytics function and led company-wide budgeting process.PATENT GROUP: Created/led Patent Management group. Initiated Deliberate Pre-emptive Intellectual Property Design strategy.PAYMENT NEGOTIATIONS: Secured payment deferrals of $20M for CMC development of lenabasum until launch.PHARMA DEVELOPMENT LEADERSHIP: Set up hybrid organization with external service providers advancing small molecule candidates from pre-clinical development to marketed product.STRATEGIC SOURCING MODEL: Transformed transactional Procurement function to Strategic Sourcing model.DRUG IN CAPSULE: Developed launch with “drug in capsule” with post-commercial follow-on to “To Be” commercial formulation of simple “Blend in Capsule” and liquid-filled soft gel.PRODUCT ADVANCEMENTS: Advanced early-stage drug product CRB-4001 to exploratory formulation for FIH studies; advanced CRB-317 preclinical asset to FIH dosing - on track for 10-month timeline from start of development to IND filed.PARTNERSHIPS: Established strategic integrated partnerships.CLINICAL SUPPLY OPERATION: Built Global Supply Chain group to support 2021 launch of lenabasum.

Led 55 employees across 7 global sites to manage external suppliers in support of Global Manufacturing & Supply (Commercial Manufacturing) and Global Pharmaceutical Development (Pre-Clinical to Launch). Controlled annual direct/indirect spend of $700M.DEVELOPMENT & SUPPLY (GPS) BUSINESS OPERATIONS LEADERSHIP: Directed support for External & Internal Pharmaceutical Development & Manufacturing (Actives & Intermediates, Formulation Development, Drug Product, Packaging & Devices), Chemicals, Excipients, Global Supply Chain, Global Logistics & Shipping and Distribution & Warehousing and site Indirect services.STRATEGIC SOURCING INTRODUCTION: Drove design/implementation of dual outsourcing strategy for drug product manufacturing of $6B brand Eliquis® to ensure business continuity targets. Established external commercial manufacturing of OPDIVO®.OPERATION EFFECTIVENESS: Initiated/drove Continuous Improvement initiatives capturing savings of +5% annually. Optimized org structures and processes improving dept. efficiency and achieving 20% staff reduction.

Developed strategy and sourced all pre-clinical and clinical small molecule intermediates and APIs, formulation development and drug product manufacturing, analytical, and associated development services. Increased overall productivity 60%.ASIA SOURCING STRATEGY: Devised, developed, and implemented Asia sourcing strategy. Migrated significant portions of Western supplier sourcing to high-quality, Low-Cost suppliers within the “R&D Innovation Zone.”

Led 4 major programs between 2000 and 2009 as an Integrated Development Team Lead. Oversaw 20+ Process Scientists to deliver numerous development programs spanning pre-clinical through launch. Drove development strategy/implementation of development assets from pre-clinical to launch, including small molecule, antibody drug conjugate, vitamin drug conjugate, and oligopeptides. Project work includes significant contributions to Baraclude®, Eliquis®, and Taxol®.